Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Variations in ORAI1 Gene Associated with Kawasaki Disease

  • Yoshihiro Onouchi ,

    Contributed equally to this work with: Yoshihiro Onouchi, Ryuji Fukazawa, Kenichiro Yamamura

    Affiliations Laboratory for Cardiovascular Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan, Department of Public Health, Graduate School of Medicine, Chiba University, Chiba, Japan

  • Ryuji Fukazawa ,

    Contributed equally to this work with: Yoshihiro Onouchi, Ryuji Fukazawa, Kenichiro Yamamura

    Affiliation Department of Pediatrics, Nippon Medical School, Tokyo, Japan

  • Kenichiro Yamamura ,

    Contributed equally to this work with: Yoshihiro Onouchi, Ryuji Fukazawa, Kenichiro Yamamura

    Affiliation Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

  • Hiroyuki Suzuki,

    Affiliation Department of Pediatrics, Wakayama Medical University, Wakayama, Japan

  • Nobuyuki Kakimoto,

    Affiliation Department of Pediatrics, Wakayama Medical University, Wakayama, Japan

  • Tomohiro Suenaga,

    Affiliation Department of Pediatrics, Wakayama Medical University, Wakayama, Japan

  • Takashi Takeuchi,

    Affiliation Department of Pediatrics, Wakayama Medical University, Wakayama, Japan

  • Hiromichi Hamada,

    Affiliation Department of Pediatrics, Tokyo Women’s Medical University Yachiyo Medical Center, Yachiyo, Japan

  • Takafumi Honda,

    Affiliation Department of Pediatrics, Tokyo Women’s Medical University Yachiyo Medical Center, Yachiyo, Japan

  • Kumi Yasukawa,

    Affiliation Department of Pediatrics, Tokyo Women’s Medical University Yachiyo Medical Center, Yachiyo, Japan

  • Masaru Terai,

    Affiliation Department of Pediatrics, Tokyo Women’s Medical University Yachiyo Medical Center, Yachiyo, Japan

  • Ryota Ebata,

    Affiliation Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, Japan

  • Kouji Higashi,

    Affiliation Department of Cardiology, Chiba Children’s Hospital, Chiba, Japan

  • Tsutomu Saji,

    Affiliation Department of Pediatrics, Toho University Medical Center, Omori Hospital, Tokyo, Japan

  • Yasushi Kemmotsu,

    Affiliation Department of Pediatrics, Toho University Medical Center, Omori Hospital, Tokyo, Japan

  • Shinichi Takatsuki,

    Affiliation Department of Pediatrics, Toho University Medical Center, Omori Hospital, Tokyo, Japan

  • Kazunobu Ouchi,

    Affiliation Department of Pediatrics, Kawasaki Medical School, Kurashiki, Japan

  • Fumio Kishi,

    Affiliation Department of Molecular Genetics, Kawasaki Medical School, Kurashiki, Japan

  • Tetsushi Yoshikawa,

    Affiliation Department of Pediatrics, Fujita Health University, Toyoake, Japan

  • Toshiro Nagai,

    Affiliation Department of Pediatrics, Dokkyo Medical University Koshigaya Hospital, Koshigaya, Japan

  • Kunihiro Hamamoto,

    Affiliation Department of Occupational Therapy, International University of Health and Welfare, Okawa, Japan

  • Yoshitake Sato,

    Affiliation Department of Pediatrics, Fuji Heavy Industry Health Insurance Society Ota Memorial Hospital, Ota, Japan

  • Akihito Honda,

    Affiliation Department of Pediatrics, Asahi General Hospital, Asahi, Japan

  • Hironobu Kobayashi,

    Affiliation Department of Pediatrics, Asahi General Hospital, Asahi, Japan

  • Junichi Sato,

    Affiliation Department of Pediatrics, Funabashi Municipal Medical Center, Funabashi, Japan

  • Shoichi Shibuta,

    Affiliation Department of Pediatrics, Kinan Hospital, Tanabe, Japan

  • Masakazu Miyawaki,

    Affiliation Department of Pediatrics, Kinan Hospital, Tanabe, Japan

  • Ko Oishi,

    Affiliation Department of Pediatrics, Hashimoto Municipal Hospital, Hashimoto, Japan

  • Hironobu Yamaga,

    Affiliation Department of Pediatrics, Naga Hospital, Kinokawa, Japan

  • Noriyuki Aoyagi,

    Affiliation Department of Pediatrics, Wakayama Rosai Hospital, Wakayama, Japan

  • Megumi Yoshiyama,

    Affiliation Department of Pediatrics, Hidaka General Hospital, Gobo, Japan

  • Ritsuko Miyashita,

    Affiliation Department of Pediatrics, Izumiotsu Municipal Hospital, Izumiotsu, Japan

  • Yuji Murata,

    Affiliation Department of Pediatrics, Sendai City Hospital, Sendai, Japan

  • Akihiro Fujino,

    Affiliation Department of Pediatric Surgery, Keio University School of Medicine, Tokyo, Japan

  • Kouichi Ozaki,

    Affiliation Laboratory for Cardiovascular Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan

  • Tomisaku Kawasaki,

    Affiliation Japan Kawasaki Disease Research Center, Tokyo, Japan

  • Jun Abe,

    Affiliation Department of Allergy & Immunology, National Center for Child Health and Development, Tokyo, Japan

  • Mitsuru Seki,

    Affiliation Department of Pediatrics, Gunma University School of Medicine, Maebashi, Japan

  • Tohru Kobayashi,

    Affiliation Department of Development Strategy, Center for Clinical Research and Development, National Center for Child Health and Development, Tokyo, Japan

  • Hirokazu Arakawa,

    Affiliation Department of Pediatrics, Gunma University School of Medicine, Maebashi, Japan

  • Shunichi Ogawa,

    Affiliation Department of Pediatrics, Nippon Medical School, Tokyo, Japan

  • Toshiro Hara,

    Current address: Fukuoka Children’s Hospital and Medical Center for Infectious Diseases, Fukuoka, Japan

    Affiliation Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

  • Akira Hata,

    Affiliation Department of Public Health, Graduate School of Medicine, Chiba University, Chiba, Japan

  •  [ ... ],
  • Toshihiro Tanaka

    Affiliations Laboratory for Cardiovascular Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan, Department of Human Genetics and Disease Diversity, Tokyo Medical and Dental University, Tokyo, Japan

  • [ view all ]
  • [ view less ]

Variations in ORAI1 Gene Associated with Kawasaki Disease

  • Yoshihiro Onouchi, 
  • Ryuji Fukazawa, 
  • Kenichiro Yamamura, 
  • Hiroyuki Suzuki, 
  • Nobuyuki Kakimoto, 
  • Tomohiro Suenaga, 
  • Takashi Takeuchi, 
  • Hiromichi Hamada, 
  • Takafumi Honda, 
  • Kumi Yasukawa


Kawasaki disease (KD; MIM#61175) is a systemic vasculitis syndrome with unknown etiology which predominantly affects infants and children. Recent findings of susceptibility genes for KD suggest possible involvement of the Ca2+/NFAT pathway in the pathogenesis of KD. ORAI1 is a Ca2+ release activated Ca2+ (CRAC) channel mediating store-operated Ca2+ entry (SOCE) on the plasma membrane. The gene for ORAI1 is located in chromosome 12q24 where a positive linkage signal was observed in our previous affected sib-pair study of KD. A common non-synonymous single nucleotide polymorphism located within exon 2 of ORAI1 (rs3741596) was significantly associated with KD (P = 0.028 in the discovery sample set (729 KD cases and 1,315 controls), P = 0.0056 in the replication sample set (1,813 KD cases vs. 1,097 controls) and P = 0.00041 in a meta-analysis by the Mantel-Haenszel method). Interestingly, frequency of the risk allele of rs3741596 is more than 20 times higher in Japanese compared to Europeans. We also found a rare 6 base-pair in-frame insertion variant associated with KD (rs141919534; 2,544 KD cases vs. 2,414 controls, P = 0.012). These data indicate that ORAI1 gene variations are associated with KD and may suggest the potential importance of the Ca2+/NFAT pathway in the pathogenesis of this disorder.


Kawasaki disease (KD; MIM #611775) is an acute febrile illness which predominantly affects infants and children younger than 5 years of age [1;2]. Principal symptoms of KD are high fever, bilateral conjunctival congestion, changes in the appearance of the lips and oral cavity, skin rash, erythema and indurative edema of hands and feet, and cervical lymphadenopathy. Although KD is a self-limited disorder, cardiac complication represented by coronary artery aneurysms occurs in 20–25% of the patients if untreated [3]. Intravenous immunoglobulin (IVIG) therapy has proven to be effective in preventing coronary artery lesions (CALs) [4]; however, 10–15% of patients poorly respond to the treatment and are at high risk for developing CALs. Currently, KD is a leading cause of acquired heart diseases in children in developed countries.

Based on observations of its seasonality in incidence and previous epidemics experienced in Japan, it is believed that infectious agents may play an important role in the pathogenesis of the disease. However, after more than 40 years since Kawasaki first described the disease [1], the etiology still remains unknown. Meanwhile, a higher prevalence in children of Asian ancestry [5;6] and evidence of familial aggregation of the disease [7;8] have strongly indicated an involvement of genetic susceptibility. Thus, the identification of genetic factors contributing to the inter-ethnic and inter-individual difference in susceptibility to KD will help to clarify disease etiology.

A genome-wide linkage analysis by the affected sib-pair method in KD previously identified 10 chromosomal regions with nominal evidence of linkage [9]. In subsequent association studies using single nucleotide polymorphisms (SNPs), two susceptibility loci for KD were successfully identified [10;11]. One is ITPKC on 19q13.2 encoding inositol 1,4,5-trisphosphate 3-kinase C which catalyzes the phosphorylation of inositol 1,4,5-trisphosphate (IP3) leading to the down regulation of signal transduction along the Ca2+/NFAT pathway. The second locus is CASP3 on 4q35 which encodes CASPASE3, a key molecule involved in apoptosis of immune cells. CASPASE3 was also reported to cleave nuclear factor of activated T-cells (NFAT) c2 [12] and the receptor for IP3 (ITPR1) [13], major components in the Ca2+/NFAT pathway signal transduction, as its substrates in T-cells. In this study, we focused on ORAI1, a CRAC channel that plays a key role in the SOCE mechanism on which various immune cells rely for activation of the Ca2+/NFAT pathway. ORAI1 is a positional candidate gene of KD located at the 12q24 region where the highest linkage signal (MLS = 2.69) was observed in the previous linkage study [9].

Materials and Methods

Ethics statement

The ethical committees or institutional review boards at RIKEN (RIKEN Yokohama Campus Ethics Committee), Chiba University (Biomedical Research Ethics Committee of the Graduate School of Medicine, Chiba University), Nippon Medical School (Nippon Medical School Ethics Committee for Human Genome / Gene Analysis Research), Kyushu University (Kyushu University Institutional Review Board for Human Genome / Gene Research), Wakayama Medical University (Research Ethics Committee of Wakayama Medical University), Tokyo Women’s Medical University (Tokyo Women's Medical University Genome Ethics Committee), Chiba Children’s hospital (Institutional Review Board of Chiba Children's Hospital), Toho University (Human Research Ethics Committee of Toho University Faculty of Medicine), Kawasaki Medical School (Research Ethics Committee of Kawasaki Medical School and Hospital), Fujita Health University (the Ethical Review Boards for Human Genome Studies at Fujita Health University), Dokkyo Medical University (Bioethical Committee of Dokkyo Medical University), Fuji Heavy Industry Health Insurance Society Ota Memorial Hospital (Fuji Heavy Industry Health Insurance Society Ota Memorial Hospital Ethics Committee), Asahi General Hospital (Ethics Committee of Asahi General Hospital), Funabashi Municipal Medical Center (Funabashi Municipal Medical Center Ethics Committee), Kinan Hospital (Ethics Committee of Kinan Hospital), Naga Hospital (Ethics Committee of Naga Hospital), Wakayama Rosai Hospital (Wakayama Rosai Hospital Ethics Committee), Hidaka General Hospital (Ethics Committee of Hidaka General Hospital), Izumiotsu Municipal Hospital (Izumiotsu Municipal Hospital Ethics Committee), Sendai City Hospital (Sendai City Hospital Ethics Committee), Keio University School of Medicine (Keio University School of Medicine, An Ethical Committee), National Center for Child Health and Development (the Ethics Committee of National Center for Child Health and Development), Gunma University (Genome Ethics Committee at Gunma University Graduate School of Medicine) and Hashimoto Municipal Hospital (Ethics Committee of Hashimoto Municipal Hospital) approved the study. We obtained written informed consent from all the participants. As KD is a childhood disease and patients were infants and children at enrollment, in most cases written informed consent was obtained from the patients’ parents. When the patients were aged 16 to 20 years, we obtained written informed consent from both the patients themselves and their parents.


We recruited 2,544 KD patients from several medical institutions in Japan. The control subjects of Japanese healthy adults were obtained from the Osaka-Midosuji Rotary Club, Osaka (n = 940), the Health Science Research Resources Bank, Osaka (n = 950) and from Keio University (n = 374). Patients with disorders unrelated to KD (n = 168) from Nippon Medical School were also enrolled as control subjects.

Selection of ORAI1 as a positional candidate gene to be studied

Based on the updated gene mapping information, we newly considered genes located within 1-lod confidence interval in linkage position on chromosome12 identified through our previous work (NC_000012.11: from 117.5 Mb– 127 Mb; Fig 1) [9]. Among the 151 genes fulfilling this criteria, we selected the ORAI1 gene, which is located near the center of the linkage area (122.1Mb), as a positional candidate gene for this study.

Re-sequencing and genotyping

We re-sequenced the ORAI1 genomic region (NC_000012.11: from nt 122,062,619 to 122,076,990) using 94 KD subjects. To identify variants efficiently, the sample panel for re-sequencing consisted of mostly probands of familial KD cases recruited in our previous affected sib-pair study [9]. The number of samples was determined to enable detection of variants with minor allele frequencies as low as 0.01. Linkage disequilibrium among 37 variants with minor allele frequency greater than 0.05 was evaluated by Haploview 4.2 software. Selection of tag SNPs were performed by using the tagger option of the software with an r-squared threshold of 0.80. Genotyping of KD cases and controls for the SNPs were carried out by using the Invader assay as described previously [14]. Insertion / deletion variants were genotyped by direct sequencing.

Statistical analysis

Association of the tag SNPs and KD was evaluated using the Pearson’s chi-square test. A meta-analysis of association data for rs3741596 in both the discovery cohort and replication cohort was conducted using the Mantel-Haenszel method. Fisher’s exact test was employed to assess association of the rare genetic variants (rs141919534 and c.59G>C) and KD. Conditional logistic regression analysis was conducted to see whether observed association of the SNPs represented by rs3741596 could be explained by linkage disequilibrium with rs76753792, the most significant SNP in the group. The Pearson’s chi-square test and meta-analysis with Mantel-Haenszel method were conducted using Microsoft Excel 2010 software. Fisher’s exact test and logistic regression analysis were conducted using the R version 2.15.2 statistical environment.

In silico prediction of the functional effects of the variants

We used the Variant Effect Predictor web tool [15] to evaluate the impact of amino acid changes of ORAI1 on its protein function. miRNA target sequences within the 3’-UTR of ORAI1 mRNA and the impact of the nucleotide changes within the targets was predicted using the mrSNP web service [16].


The experimental flow of this study was shown in Fig 1. Re-sequencing of the ORAI genomic region resulted in the identification of 69 variants (S1 Table). A linkage disequilibrium analysis including 37 polymorphisms with minor allele frequencies larger than 0.05 revealed 9 groups of polymorphisms which showed strong linkage disequilibrium (r2 > 0.8; Fig 2). To evaluate the association of these common polymorphisms with KD efficiently, we selected one representative SNP from each group and genotyped 730 KD cases and 1,318 controls at these loci. In this screening, one tag SNP (rs3741596) representing a group with 10 SNPs showed a nominal association (OR = 1.19, 95%CI 1.02–1.40, P = 0.028; Table 1). We then examined the association of rs3741596 in another case-control series (1,813 KD cases and 1,097 controls) for validation. As shown in Table 2, rs3741596 showed a similar association (OR = 1.22, 95%CI 1.06–1.40, P = 0.0056) and a meta-analysis of data from both discovery and validation cohorts indicated a statistically significant combined result (OR = 1.21, 95%CI 1.09–1.34 P = 0.00041). Analysis of the 9 other SNPs tagged by rs3741596 among the initial screening case-control series showed the same trend of association for all variants and only minor differences in odds ratios and P values (S2 Table). The lowest P value was observed for rs76753792 located within the 3’ untranslated region (UTR) of the gene, and the nucleotide change was predicted to alter binding affinity of miRNAs to the surrounding mRNA sequence (S3 Table). However, conditional logistic regression analyses did not indicate this SNP to be superior over the other 9 SNPs (data not shown).

Fig 2. Linkage disequilibrium map of the common variants around the ORAI1 gene.

Upper: Genomic structure of the ORAI1 gene. Middle: Positions and sizes of PCR amplicons. Lower: Results of pairwise LD analyses of the identified variants with minor allele frequencies greater than 0.05 (lower). r-squared values for each variant pair are presented in grayscale.

Table 1. Association of tagging SNPs in the ORAI1 region with KD.

Next, we investigated the possible involvement of rare genetic variants of this gene in KD susceptibility. We identified 32 variants with minor allele frequencies of less than 0.05 including 4 in the upstream region of the gene, 5 in exons and 23 in introns (S1 Table). There were no exonic and intronic variants within known consensus sequences of splicing acceptor or donor sites. Among the 5 exonic variants, one single nucleotide variant (SNV) (c.59G>C; p.G20A) and one 6-bp insertion variant (rs141919534, c.126-7insCCGCCA; p.42A_p.43PinsPP) appeared to alter ORAI1 protein sequence, and the other 3 included a synonymous SNV and 2 3’-UTR variants. We further investigated the c.59G>C SNV and rs141919534 with respect to directly altering the ORAI protein sequence. We first assessed the association of rs141919534 because the 6-bp insertion results in elongation of a proline repeat located within the N-terminal cytoplasmic domain of ORAI1 (S1 Fig) which is thought to directly interact with STIM1, the endoplasmic counterpart of ORAI1 [17;18]. We genotyped all cases and controls for this variation and found that the 6-bp insertion was over-represented among KD patients (OR = 3.80, 95%CI 1.23–15.64, P = 0.012; Table 3). Results of haplotype inference indicated that the 6-bp insertion had occurred on a chromosome bearing the major allele of rs3741596 (S2 Fig). No haplotype effect was observed between these two variants when examining haplotype associations (data not shown). In contrast, we failed to detect an association for the c.59G>C SNV, also located within N terminal cytoplasmic domain, in the case and control panel used in the initial screening of the tag SNPs (S4 Table).


ORAI1 was identified as a membrane bound Ca2+ channel protein essential for SOCE of T lymphocytes [19]. ORAI1 is activated by direct interaction with STIM1 which is expressed on the endoplasmic reticulum (ER) membrane and acts as a sensor of Ca2+ store depletion in the ER. When inositol 1,4,5-trisphosphate (IP3) generated by hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) in response to signals from stimulated cell surface receptors (T-cell, B-cell, Immunoglobulin G Fc receptors, etc.) binds to the IP3 receptor (IP3R) on the ER membrane, changes in conformation of the IP3R molecule and tertiary structure of their tetramer complex are induced, and flux of Ca2+ stored within the ER lumen through IP3R is evoked. When depletion of stored Ca2+ in the ER is sensed by STIM1 with its EF-hand domain, multiple STIM1 and ORAI1 molecules interact directly and form complexes. This complex formation leads to conformational changes of the pore-lining transmembrane domain of ORAI1 to gate the channel for Ca2+ entry from the extra cellular space into the cytoplasm. Increase of cytosolic Ca2+ leads to the activation of calcineurin and the dephosphorylation and nuclear translocation of NFAT. This series of reactions, referred to as SOCE [2023], is essential for T-cell activation, and deficiency of either ORAI1 or STIM1 causes autosomal recessive primary immune deficiency syndromes (MIM: 612782 or 612783) [24;25]. Analysis of mice homozygously expressing nonfunctional Orai1 in the hematopoietic tissue revealed a critical role for Orai1 in T-cell mediated autoimmunity and allograft rejection [26]. It is known that ORAI1 and STIM1 are expressed also in other hematopoietic cells such as B-cells [27], dendritic cells [28], neutrophils [29], NK cells [30], platelets [31] and mast cells [32;33]. ORAI1 and STIM1 regulate proliferation, apoptosis and metastasis of various cancer cells [34]. Involvement of these two molecules in activation and proliferation of human umbilical vein endothelial cells has also been reported [35;36]. Thus, SOCE is not recognized as a phenomena restricted to the immune system. Given that many types of immune and vascular endothelial cells are activated and contribute to KD pathogenesis, dysregulation of the mechanism could be one pathophysiological basis of KD vasculitis.

The previous identification of KD-associated SNPs within ITPKC and CASP3 and their presumed role as negative regulators of the Ca2+/NFAT pathway led us to suspect genes involved in this pathway as candidate susceptibility loci for KD. ORAI1, which plays a pivotal role in SOCE, a form of Ca2+/NFAT signal transduction in the abovementioned types of cells, is located near the highest linkage peak (12q24) observed in our previous affected sib-pair study [9]. In the current study, we observed a KD association with one common variant (rs3741596) and a rare polymorphism (rs141919534) of ORAI1 in the Japanese population.

SNPs of the ORAI1 gene region and/ or their combinations have been associated with other inflammatory diseases as well, such as atopic dermatitis, ankylosing spondylitis or rheumatoid arthritis and calcium nephrolithiasis [3740]. A previous study described an association of the rs3741596 G allele with susceptibility to atopic dermatitis in Japanese [34]. Interestingly, in the Taiwanese population, it was reported that rs3741596 G allele is much less frequent (< 1%) than in Japanese (17%—19% in this study), and tag SNPs of ORAI1 were not associated with KD [41]. Considering the wide variety of tissues or cells which express ORAI1 mRNA under different regulatory mechanisms and differences in cell types playing major roles in disease pathogenesis, it might be possible that responsible variants differ from disease to disease and, conversely, the Taiwanese population has no common ORAI1 variants relevant to KD. rs3741596 alters translation of the 218th amino acid within the 2nd extra cellular loop of ORAI1 from serine to glycine (S1 Fig). In contrast to the known importance of the first extracellular loop in Ca2+ selectivity [42;43], the precise role of the 2nd extracellular loop is not known. Less conservation of the amino acid sequence around rs3741596 across species and the result of in silico prediction of the impact of the sequence alteration on protein function (S3 Fig) do not support rs3741596 as the casual variant. An LD analysis of the genotype data from the 1000 Genomes database revealed that there are 82 variants tightly linked to rs3741596 (r2 > 0.8) in the Japanese population which are distributed across a 100-kb genomic region (S5 Table). Within this 100-kb region, there is another gene whose expression or function could be affected by the associated variant(s). Function of the gene product, membrane occupation and recognition nexus repeat containing 3 (MORN3), has not been functionally characterized. However in mice, from its specific expression in testis and its property of binding to meiosis expressed gene 1 (Meg1), a regulator of spermatogenesis, it has been suggested that Morn3 also plays a role in sperm formation [44]. Based on this suspected biology, currently there is little evidence to consider MORN3 as a candidate gene in KD susceptibility.

The 6-bp insertion allele of rs141919534 is exclusively linked to the A allele at rs3741596, the non-risk allele at this locus (S2 Fig), indicating that the observed association of this insertion / deletion variant is not a spurious one due to LD between these two sites. No other variant in strong LD (r2 > 0.8) with rs141919534 was identified in the analysis of 1000 Genomes data. Taken together, although further details remain to be elucidated, we concluded that ORAI1 is a novel susceptibility gene for KD. At present, the precise impact of the 2 amino acid elongation is not clear. In light of the possible importance of the N terminal cytoplasmic domain of ORAI1 in interaction with STIM1 [17;18] and marked activation of various immune cells expressing ORAI1 in the acute phase of KD [45], it is likely that tertiary structure modified by the 2 amino acid elongation results in up-regulation of the affinity between STIM1 and ORAI1, which in turn makes the cells prone to activation. Involvement of SOCE in regulating Cyclooxygenase-2 (COX-2) gene expression in colorectal cancer cells has been documented [46;47]. Notably, cyclooxygenases is targeted by Aspirin, a non-steroidal anti-inflammatory agent administered to most of the KD patients as a part of standard treatment. It is also possible that the ORAI1 variants play a significant role in mechanisms other than SOCEs. In neutrophils, which are markedly activated in the acute phase of KD and whose infiltration into the vascular wall has been considered as a major cause of vascular damage in early stages [48], STIM1 mediates SOCE following tyrosine kinase or G protein coupled receptor signaling [49]. However, it is also known that ORAI1 mediates C5a induced neutrophil migration independently from STIM1 and SOCE [50]. Further investigation is warranted to evaluate the impact of the variant on ORAI1 function as well as on disease pathogenesis.

Epidemiological findings have indicated that notable predilection of KD to East Asian ethnicities attribute to genetic background rather than geographic factors. Marked differences in KD risk by genetic background can be explained by differences in allele frequencies of susceptibility loci. We believe ORAI1 is likely one genetic factor accounting for the observed inter-ethnic difference between children of Japanese and European ancestry. Based on 1000 Genomes data, the 83 variants associated with this locus were rare in the CEU populations when compared to the JPT populations in which minor alleles were nearly 20 times more frequent (S5 Table). Interestingly, as reported in the 1000 Genomes, the risk allele of rs3741596 (G) is considered to be an ancestral allele of this SNP, but is almost absent in gene pools in populations other than East Asians and those of African descent (S4 Fig). It is not clear whether the skewed allele distribution is due to difference in selection pressure among areas or to some other event such as a population bottleneck. However, it is highly probable that the rs3741596 G allele originated from a founder haplotype because the LD pattern between rs3741596 and other variants are conserved (S5 Table).

None of the 83 variants were part of the genotyping microarrays used in previous GWAS studies of KD. The insufficient coverage of the genomic region containing ORAI1 by the SNP arrays is likely why associations at this locus had not been detected in our previous GWAS [51]. Insufficient statistical power in previous GWAS due to limits in sample sizes (several hundreds) have contributed to missed associations. However, it is also possible that there are a number of susceptibility genes for KD which have not been identified for the same reason as ORAI1. To our knowledge, ORAI1 is the first gene of which both common and rare variants confer susceptibility to KD. Recently, increased attention has been given to rare genetic variants as a source of missing heritability. A genome-wide rare variant association study seems, at least at this moment, unrealistic considering the estimated number of samples required for a well-powered study (> 25,000) [52] and its enormous cost. Thus, investigating known susceptibility genes, as well as genes that directly or indirectly interact with them, may be an effective way of identifying rare variants related to KD.

In conclusion, we identified common and rare variants of ORAI1 genes associated with KD. Further investigation of the role of the gene in the pathophysiology of KD is warranted.

Supporting Information

S1 Fig. A diagram of ORAI1 four trans-membrane protein and the positions of the three variants affecting ORAI1 protein sequence.


S2 Fig. Haplotypes and genotype combinations with two associated variants of the ORAI1 gene in this study.


S3 Fig. Prediction of impact of the amino acid sequence alterations on ORAI1 function.


S4 Fig. Distribution of rs3741596 alleles in HapMap populations.


S2 Table. Association results of the SNPs tagged by rs3741596 with KD.


S3 Table. miRNAs which bind differently to the surrounding sequences of the 3'-UTR SNPs tagged with rs3741596


S4 Table. Association result of the c.59G>C variant of ORAI1 gene with KD.


S5 Table. Frequencies and positions of the group of variants tagged by rs3741596.



The following authors participated in this work as members of Japan Kawasaki Disease Genome Consortium: Yoshihiro Onouchi, Ryuji Fukazawa, Kenichiro Yamamura, Hiroyuki Suzuki, Nobuyuki Kakimoto, Tomohiro Suenaga, Takashi Takeuchi, Hiromichi Hamada, Takafumi Honda, Kumi Yasukawa, Masaru Terai, Ryota Ebata, Kouji Higashi, Tsutomu Saji, Yasushi Kemmotsu, Shinichi Takatsuki, Kazunobu Ouchi, Jun Abe, Mitsuru Seki, Tohru Kobayashi, Hirokazu Arakawa, Shunichi Ogawa, and Toshiro Hara. We are grateful to all the participants of this study and the medical staff caring for the patients. We appreciate Ms. Katsuko Honjo, Ms. Tamami Tanaka, Ms. Yoshie Kikuchi and Ms. Saori Kawakami for their technical assistance. We also thank Dr. Kevin Urayama for careful proofreading of the manuscript.

Author Contributions

Conceived and designed the experiments: YO. Performed the experiments: YO RF K. Yamamura K.Ozaki. Analyzed the data: YO. Contributed reagents/materials/analysis tools: YO RF K. Yamamura HS NK T. Suenaga T. Takeuchi HH T. Honda K. Yasukawa MT RE K. Higashi T. Saji YK ST K. Ouchi FK TY TN K. Hamamoto YS A. Honda HK JS SS MM K. Oishi HY NA MY RM YM AF T. Kawasaki JA MS T. Kobayashi HA SO T. Hara. Wrote the paper: YO K. Ozaki A. Hata T. Tanaka.


  1. 1. Kawasaki T (1967) [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children]. Arerugi 16: 178–222. pmid:6062087
  2. 2. Burns JC (2002) Commentary: translation of Dr. Tomisaku Kawasaki's original report of fifty patients in 1967. Pediatr Infect Dis J 21: 993–995. pmid:12442017
  3. 3. Kato H, Koike S, Yamamoto M, Ito Y, Yano E, Kato (1975) Coronary aneurysms in infants and young children with acute febrile mucocutaneous lymph node syndrome. J Pediatr 86: 892–898. pmid:236368
  4. 4. Furusho K, Sato K, Soeda T, Matsumoto H, Okabe T, Hirota T, et al. (1983) High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 2: 1359.
  5. 5. Davis RL, Waller PL, Mueller BA, Dykewicz CA, Schonberger LB (1995) Kawasaki syndrome in Washington State. Race-specific incidence rates and residential proximity to water. Arch Pediatr Adolesc Med 149: 66–69. pmid:7827664
  6. 6. Holman RC, Christensen KY, Belay ED, Steiner CA, Effler PV, Miyamura J, et al. (2010) Racial/ethnic differences in the incidence of Kawasaki syndrome among children in Hawaii. Hawaii Med J 69: 194–197. pmid:20845285
  7. 7. Fujita Y, Nakamura Y, Sakata K, Hara N, Kobayashi M, Nagai M, et al. (1989) Kawasaki disease in families. Pediatrics 84: 666–669. pmid:2780128
  8. 8. Uehara R, Yashiro M, Nakamura Y, Yanagawa H (2004) Clinical features of patients with Kawasaki disease whose parents had the same disease. Arch Pediatr Adolesc Med 158: 1166–1169. pmid:15583102
  9. 9. Onouchi Y, Tamari M, Takahashi A, Tsunoda T, Yashiro M, Nakamura Y, et al. (2007) A genomewide linkage analysis of Kawasaki disease: evidence for linkage to chromosome 12. J Hum Genet 52: 179–190. pmid:17160344
  10. 10. Onouchi Y, Gunji T, Burns JC, Shimizu C, Newburger JW, Yashiro M, et al. (2008) ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet 40: 35–42. pmid:18084290
  11. 11. Onouchi Y, Ozaki K, Burns JC, Shimizu C, Hamada H, Honda H, et al. (2010) Common variants in CASP3 confer susceptibility to Kawasaki disease. Hum Mol Genet 19: 2898–2906. pmid:20423928
  12. 12. Wu W, Misra RS, Russell JQ, Flavell RA, Rincón M, Budd RC (2006) Proteolytic regulation of nuclear factor of activated T (NFAT) c2 cells and NFAT activity by caspase-3. J Biol Chem 281: 10682–10690. pmid:16455648
  13. 13. Hirota J, Furuichi T, Mikoshiba K (1999) Inositol 1,4,5-trisphosphate receptor type 1 is a substrate for caspase-3 and is cleaved during apoptosis in a caspase-3-dependent manner. J Biol Chem 274: 34433–34437. pmid:10567423
  14. 14. Ohnishi Y, Tanaka T, Ozaki K, Yamada R, Suzuki H, Nakamura Y (2001) A high-throughput SNP typing system for genome-wide association studies. J Hum Genet 46: 471–477. pmid:11501945
  15. 15. McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F (2010) Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics 26: 2069–2070. pmid:20562413
  16. 16. Deveci M, Catalyürek UV, Toland AE (2014) mrSNP: software to detect SNP effects on microRNA binding. BMC Bioinformatics 15: 73. pmid:24629096
  17. 17. Soboloff J, Spassova MA, Tang XD, Hewavitharana T, Xu W, Gill DL (2006) Orai1 and STIM reconstitute store-operated calcium channel function. J Biol Chem 281: 20661–20665. pmid:16766533
  18. 18. Zheng H, Zhou MH, Hu C, Kuo E, Peng X, Hu J, et al. (2013) Differential roles of the C and N termini of Orai1 protein in interacting with stromal interaction molecule 1 (STIM1) for Ca2+ release-activated Ca2+ (CRAC) channel activation. J Biol Chem 288: 11263–11272. pmid:23447534
  19. 19. Vig M, Peinelt C, Beck A, Koomoa DL, Rabah D, Koblan-Huberson M, et al. (2006) CRACM1 is a plasma membrane protein essential for store-operated Ca2+ entry. Science 312: 1220–1223. pmid:16645049
  20. 20. Streb H, Irvine RF, Berridge MJ, Schulz I (1983) Release of Ca2+ from a nonmitochondrial intracellular store in pancreatic acinar cells by inositol-1,4,5-trisphosphate. Nature 306: 67–69. pmid:6605482
  21. 21. Berridge MJ (1993) Inositol trisphosphate and calcium signalling. Nature 361: 315–325. pmid:8381210
  22. 22. Lewis RS (2001) Calcium Signaling Mechanisms in T Lymphocytes. Annu Rev Immunol 19: 497–521. pmid:11244045
  23. 23. Putney JW Jr (1986) A model for receptor-regulated calcium entry. Cell Calcium 7: 1–12. pmid:2420465
  24. 24. Feske S, Gwack Y, Prakriya M Srikanth S, Puppel SH, Tanasa B, et al. (2006) A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function. Nature 441: 179–185. pmid:16582901
  25. 25. Picard C, McCarl CA, Papolos A, Khalil S, Lüthy K, Hivroz C, et al. (2009) STIM1 mutation associated with a syndrome of immunodeficiency and autoimmunity. New Eng J Med 360: 1971–1980. pmid:19420366
  26. 26. McCarl CA, Khalil S, Ma J, Oh-hora M, Yamashita M, Roether J, et al. (2010) Store-operated Ca2+ entry through ORAI1 is critical for T cell-mediated autoimmunity and allograft rejection. J Immunol 185: 5845–5858. pmid:20956344
  27. 27. Baba Y, Kurosaki T (2011) Impact of Ca2+ signaling on B cell function. Trends Immunol 32: 589–594. pmid:22000665
  28. 28. Félix R, Crottès D, Delalande A, Fauconnier J, Lebranchu Y, Le Guennec JY, et al. (2013) The Orai-1 and STIM-1 complex controls human dendritic cell maturation. PLoS One 8: e61595. pmid:23700407
  29. 29. Steinckwich N, Schenten V, Melchior C, Bréchard S, Tschirhart EJ (2011) An essential role of STIM1, Orai1, and S100A8-A9 proteins for Ca2+ signaling and FcγR-mediated phagosomal oxidative activity. J Immunol 186: 2182–2191. pmid:21239714
  30. 30. Maul-Pavicic A, Chiang SC, Rensing-Ehl A, Jessen B, Fauriat C, Wood SM, et al. (2011) ORAI1-mediated calcium influx is required for human cytotoxic lymphocyte degranulation and target cell lysis. Proc Natl Acad Sci U S A 108: 3324–3329. pmid:21300876
  31. 31. Tolhurst G, Carter RN, Amisten S, Holdich JP, Erlinge D, Mahaut-Smith MP (2008) Expression profiling and electrophysiological studies suggest a major role for Orai1 in the store-operated Ca2+ influx pathway of platelets and megakaryocytes. Platelets 19: 08–33.
  32. 32. Vig M, DeHaven WI, Bird GS, Billingsley JM, Wang H, Rao PE (2008) Defective mast cell effector functions in mice lacking the CRACM1 pore subunit of store-operated calcium release-activated calcium channels. Nat Immunol 9: 89–96. pmid:18059270
  33. 33. Baba Y, Nishida K, Fujii Y, Hirano T, Hikida M, Kurosaki T (2008) Essential function for the calcium sensor STIM1 in mast cell activation and anaphylactic responses. Nat Immunol 9: 81–88. pmid:18059272
  34. 34. Bergmeier W, Weidinger C, Zee I, Feske S (2013) Emerging roles of store-operated Ca²⁺ entry through STIM and ORAI proteins in immunity, hemostasis and cancer. Channels 7: 379–391. pmid:23511024
  35. 35. Zhou MH, Zheng H, Si H, Jin Y, Peng JM, He L, et al. (2014) Stromal interaction molecule 1 (STIM1) and Orai1 mediate histamine-evoked calcium entry and nuclear factor of activated T-cells (NFAT) signaling in human umbilical vein endothelial cells. J Biol Chem 289: 29446–29456. pmid:25190815
  36. 36. Abdullaev IF, Bisaillon JM, Potier M, Gonzalez JC, Motiani RK, Trebak M (2008) Stim1 and Orai1 mediate CRAC currents and store-operated calcium entry important for endothelial cell proliferation. Circ Res 103: 1289–1299. pmid:18845811
  37. 37. Chang WC, Lee CH, Hirota T, Wang LF, Doi S, Miyatake A, et al. (2012) ORAI1 genetic polymorphisms associated with the susceptibility of atopic dermatitis in Japanese and Taiwanese populations. PLoS One 7: e29387. pmid:22253717
  38. 38. Wei JC, Yen JH, Juo SH, Chen WC, Wang YS, Chiu YC, et al. (2011) Association of ORAI1 haplotypes with the risk of HLA-B27 positive ankylosing spondylitis. PLoS One 6: e20426. pmid:21674042
  39. 39. Yen JH, Chang CM, Hsu YW, Lee CH, Wu MS, Hwang DY, et al. (2014) A polymorphism of ORAI1 rs7135617, is associated with susceptibility to rheumatoid arthritis. Mediators Inflamm 2014: 834831. pmid:24808640
  40. 40. Chou YH, Juo SH, Chiu YC, Liu ME, Chen WC, Chang CC, et al. (2011) A polymorphism of the ORAI1 gene is associated with the risk and recurrence of calcium nephrolithiasis. J Urol 185: 1742–1746. pmid:21420116
  41. 41. Kuo HC, Lin YJ, Juo SH, Hsu YW, Chen WC, Yang KD, et al. (2011) Lack of Association between ORAI1/CRACM1 Gene Polymorphisms and Kawasaki Disease in the Taiwanese Children. J Clin Immunol 31: 650–655. pmid:21487896
  42. 42. Yeromin AV, Zhang SL, Jiang W, Yu Y, Safrina O, Cahalan MD (2006) Molecular identification of the CRAC channel by altered ion selectivity in a mutant of Orai Nature 443: 226–229. pmid:16921385
  43. 43. Prakriya M, Feske S, Gwack Y, Srikanth S, Rao A, Hogan PG (2006) Orai1 is an essential pore subunit of the CRAC channel. Nature 443: 230–233. pmid:16921383
  44. 44. Zhang L, Shang XJ, Li HF, Shi YQ, Li W, Teves ME, et al. (2015) Characterization of membrane occupation and recognition nexus repeat containing 3, meiosis expressed gene 1 binding partner, in mouse male germ cells. Asian J Androl 17: 86–93. pmid:25248657
  45. 45. Leung DY (1989) Immunomodulation by intravenous immune globulin in Kawasaki disease. J Allergy Clin Immunol 84: 588–593. pmid:2677095
  46. 46. Wang JY, Chen BK, Wang YS, Tsai YT, Chen WC, Chang WC, et al. (2012) Involvement of store-operated calcium signaling in EGF-mediated COX-2 gene activation in cancer cells. Cell Signal 24: 162–169. pmid:21924350
  47. 47. Wang JY, Sun J, Huang MY, Wang YS, Hou MF, Sun Y, et al. (2015) STIM1 overexpression promotes colorectal cancer progression, cell motility and COX-2 expression. Oncogene. 34: 4358–4367. pmid:25381814
  48. 48. Takahashi K, Oharaseki T, Naoe S, Wakayama M, Yokouchi Y (2005) Neutrophilic involvement in the damage to coronary arteries in acute stage of Kawasaki disease. Pediatr Int 47: 305–310. pmid:15910456
  49. 49. Zhang H, Clemens RA, Liu F, Hu Y, Baba Y, Theodore P, et al. (2014) STIM1 calcium sensor is required for activation of the phagocyte oxidase during inflammation and host defense. Blood 123: 2238–2249. pmid:24493668
  50. 50. Sogkas G, Vögtle T, Rau E, Gewecke B, Stegner D, Schmidt RE, et al. (2015) Orai1 controls C5a-induced neutrophil recruitment in inflammation. Eur J Immunol. 45: 2143–2153. pmid:25912155
  51. 51. Onouchi Y, Ozaki K, Burns JC, Shimizu C, Terai M, Hamada H, et al. (2012) A genome-wide association study identifies three new risk loci for Kawasaki disease. Nat Genet 44: 517–521. pmid:22446962
  52. 52. Zuk O, Schaffner SF, Samocha K, Do R, Hechter E, Kathiresan S, et al. (2014) Searching for missing heritability: designing rare variant association studies. Proc Natl Acad Sci U S A 111: E455–464. pmid:24443550